
Yahoo · 30 de oct de 2026
Abbott Laboratories has seen a mixed share price record in recent years, which raises a straightforward question for anyone following the stock: Are the cash fl…
ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Últimos 235 días · 12/11/25 — 29/10/26
-9.83%
Precio
$ 44.000
Var. %
+2,47%
Volumen operado
1.976
Precio ABT
US$ 106,21
Teórico (precio / ratio)
ABT ÷ 4
US$ 26,55
Yield y fechas del subyacente vía Yahoo Finance. Ver calendario de dividendos.
Yield (USD)
2,4 %
Frecuencia (estimada)
Trim.
Próxima ex-date
sin fecha
Próximo pago
15/11
Cobro estimado (anual)
Dividendo anual USD ÷ ratio 4
USD 0,63
Sí, existe el CEDEAR de ABT (Abbott Labs) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es ABT.
El ticker del CEDEAR de Abbott Labs en Argentina es ABT. La acción subyacente cotiza en NYSE con el símbolo ABT.
El CEDEAR ABT tiene un ratio de 4:1. Eso significa que 4 CEDEARs equivalen a 1 acción de ABT.
El CEDEAR ABT cotiza hoy a $ 44.000 en pesos argentinos, con una variación diaria de +2,47%.
Otros CEDEARs de Salud.

Yahoo · 30 de oct de 2026
Abbott Laboratories has seen a mixed share price record in recent years, which raises a straightforward question for anyone following the stock: Are the cash fl…

Yahoo · 30 de oct de 2026
Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Human Papillomavirus (HPV) Genotyping Panels Market Global Report 2026" has been added to ResearchAndMarkets.com's of…

Yahoo · 30 de oct de 2026
Precio de cierre en pesos argentinos. Fuente: data912.
Cotización
US$ 28,10
vs teórico
+5,83%
Cotización MEP implícita
$ 1.565,84
Cotización
US$ 25,88
vs teórico
-2,53%
Cotización Cable implícita
$ 1.700,15
La acción subyacente ABT (Abbott Labs) cotiza a US$ 106,21 en su mercado de origen (NYSE).
El precio teórico del CEDEAR ABT se calcula dividiendo el precio de ABT por el ratio (4). Hoy resulta en US$ 26,55.
En BYMA podés operar ABT en pesos, ABTD en dólar MEP y ABTC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR ABT en pesos argentinos, con datos de data912.
Some of the stock trades made by members of the House and Senate might surprise you.

Yahoo · 30 de oct de 2026
Boost ROI with home INR analyzers, recurring consumable sales, distribution partnerships, and local assembly to reduce tariff exposure and testing costs.Dublin,…

Yahoo · 30 de oct de 2026
Dexcom, known for its G-series of diabetes wearables, topped September-quarter expectations late Thursday, leading to a guidance hike.

Yahoo · 30 de oct de 2026
New York-listed Perrigo said the divesture follows a strategic review, concluding a sale is the “best path forward for the business and its stakeholders”.

Yahoo · 29 de oct de 2026
AbbVie built its empire on a single blockbuster drug, then watched biosimilars gut it almost overnight. Whether the replacement pipeline saved investors or left…

Yahoo · 29 de oct de 2026
Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "South & Central America Point of Care Diagnostics Market Size and Forecast (2021 - 2031), Regional Share, Trend, and…
Noticias vía Finnhub